CA3162141A1 - Presbyopia treatments - Google Patents
Presbyopia treatments Download PDFInfo
- Publication number
- CA3162141A1 CA3162141A1 CA3162141A CA3162141A CA3162141A1 CA 3162141 A1 CA3162141 A1 CA 3162141A1 CA 3162141 A CA3162141 A CA 3162141A CA 3162141 A CA3162141 A CA 3162141A CA 3162141 A1 CA3162141 A1 CA 3162141A1
- Authority
- CA
- Canada
- Prior art keywords
- improvement
- pilocarpine
- composition
- baseline
- high contrast
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 201000010041 presbyopia Diseases 0.000 title claims abstract description 54
- 238000011282 treatment Methods 0.000 title claims abstract description 41
- 239000000203 mixture Substances 0.000 claims abstract description 380
- 230000006872 improvement Effects 0.000 claims abstract description 125
- 230000004438 eyesight Effects 0.000 claims abstract description 115
- RNAICSBVACLLGM-GNAZCLTHSA-N pilocarpine hydrochloride Chemical compound Cl.C1OC(=O)[C@@H](CC)[C@H]1CC1=CN=CN1C RNAICSBVACLLGM-GNAZCLTHSA-N 0.000 claims description 131
- 229960002139 pilocarpine hydrochloride Drugs 0.000 claims description 131
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 73
- 230000000694 effects Effects 0.000 claims description 48
- 208000001491 myopia Diseases 0.000 claims description 42
- KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 claims description 37
- 239000004327 boric acid Substances 0.000 claims description 37
- 239000011780 sodium chloride Substances 0.000 claims description 37
- 230000004304 visual acuity Effects 0.000 claims description 36
- 229960000686 benzalkonium chloride Drugs 0.000 claims description 35
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 claims description 35
- 229960000999 sodium citrate dihydrate Drugs 0.000 claims description 35
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 24
- 230000009467 reduction Effects 0.000 claims description 11
- 239000004615 ingredient Substances 0.000 claims description 9
- 239000013543 active substance Substances 0.000 claims description 6
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 claims description 6
- 238000011200 topical administration Methods 0.000 claims 3
- QCHFTSOMWOSFHM-WPRPVWTQSA-N (+)-Pilocarpine Chemical compound C1OC(=O)[C@@H](CC)[C@H]1CC1=CN=CN1C QCHFTSOMWOSFHM-WPRPVWTQSA-N 0.000 abstract description 184
- QCHFTSOMWOSFHM-UHFFFAOYSA-N SJ000285536 Natural products C1OC(=O)C(CC)C1CC1=CN=CN1C QCHFTSOMWOSFHM-UHFFFAOYSA-N 0.000 abstract description 171
- 229960001416 pilocarpine Drugs 0.000 abstract description 171
- 238000009472 formulation Methods 0.000 abstract description 116
- 238000000034 method Methods 0.000 abstract description 108
- 210000001508 eye Anatomy 0.000 description 138
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 39
- 206010052143 Ocular discomfort Diseases 0.000 description 38
- 229920000642 polymer Polymers 0.000 description 36
- WYWIFABBXFUGLM-UHFFFAOYSA-N oxymetazoline Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C)=C1CC1=NCCN1 WYWIFABBXFUGLM-UHFFFAOYSA-N 0.000 description 33
- 230000002411 adverse Effects 0.000 description 31
- HRXKRNGNAMMEHJ-UHFFFAOYSA-K trisodium citrate Chemical compound [Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O HRXKRNGNAMMEHJ-UHFFFAOYSA-K 0.000 description 31
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 29
- 230000008859 change Effects 0.000 description 25
- 206010047513 Vision blurred Diseases 0.000 description 22
- 239000004480 active ingredient Substances 0.000 description 20
- 239000003814 drug Substances 0.000 description 18
- 210000000744 eyelid Anatomy 0.000 description 18
- 229940079593 drug Drugs 0.000 description 17
- 210000000695 crystalline len Anatomy 0.000 description 16
- 229960001528 oxymetazoline Drugs 0.000 description 16
- 239000003755 preservative agent Substances 0.000 description 15
- 206010015958 Eye pain Diseases 0.000 description 14
- 206010020565 Hyperaemia Diseases 0.000 description 14
- 238000004458 analytical method Methods 0.000 description 14
- 230000001965 increasing effect Effects 0.000 description 14
- 230000002335 preservative effect Effects 0.000 description 14
- 208000010412 Glaucoma Diseases 0.000 description 13
- 239000006196 drop Substances 0.000 description 13
- 230000000007 visual effect Effects 0.000 description 13
- 241000347881 Kadua laxiflora Species 0.000 description 12
- 229960002645 boric acid Drugs 0.000 description 11
- 229960000443 hydrochloric acid Drugs 0.000 description 11
- 229960002668 sodium chloride Drugs 0.000 description 11
- 206010020675 Hypermetropia Diseases 0.000 description 10
- 206010034960 Photophobia Diseases 0.000 description 10
- 201000006318 hyperopia Diseases 0.000 description 10
- 230000004305 hyperopia Effects 0.000 description 10
- 208000013469 light sensitivity Diseases 0.000 description 10
- 210000001747 pupil Anatomy 0.000 description 10
- 238000012216 screening Methods 0.000 description 10
- 230000008961 swelling Effects 0.000 description 10
- 210000000795 conjunctiva Anatomy 0.000 description 9
- 229940039014 isoptocarpine Drugs 0.000 description 9
- 238000012360 testing method Methods 0.000 description 9
- 206010019233 Headaches Diseases 0.000 description 8
- 208000006550 Mydriasis Diseases 0.000 description 8
- 206010037538 Pupils unequal Diseases 0.000 description 8
- 208000001239 anisocoria Diseases 0.000 description 8
- 238000011156 evaluation Methods 0.000 description 8
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 8
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 8
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 8
- 230000004297 night vision Effects 0.000 description 8
- 230000000699 topical effect Effects 0.000 description 8
- 208000002193 Pain Diseases 0.000 description 7
- 201000009310 astigmatism Diseases 0.000 description 7
- 230000001886 ciliary effect Effects 0.000 description 7
- 230000004313 glare Effects 0.000 description 7
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 7
- 230000004379 myopia Effects 0.000 description 7
- BEEDODBODQVSIM-UHFFFAOYSA-N oxymetazoline hydrochloride Chemical compound Cl.CC1=CC(C(C)(C)C)=C(O)C(C)=C1CC1=NCCN1 BEEDODBODQVSIM-UHFFFAOYSA-N 0.000 description 7
- 229960005162 oxymetazoline hydrochloride Drugs 0.000 description 7
- 201000006327 accommodative esotropia Diseases 0.000 description 6
- 230000004397 blinking Effects 0.000 description 6
- OSVXSBDYLRYLIG-UHFFFAOYSA-N dioxidochlorine(.) Chemical compound O=Cl=O OSVXSBDYLRYLIG-UHFFFAOYSA-N 0.000 description 6
- 231100000673 dose–response relationship Toxicity 0.000 description 6
- 239000011521 glass Substances 0.000 description 6
- 231100000869 headache Toxicity 0.000 description 6
- 230000004410 intraocular pressure Effects 0.000 description 6
- 210000003205 muscle Anatomy 0.000 description 6
- 230000002829 reductive effect Effects 0.000 description 6
- 206010052140 Eye pruritus Diseases 0.000 description 5
- 241000283973 Oryctolagus cuniculus Species 0.000 description 5
- 208000003251 Pruritus Diseases 0.000 description 5
- 238000000149 argon plasma sintering Methods 0.000 description 5
- 210000004209 hair Anatomy 0.000 description 5
- 238000002347 injection Methods 0.000 description 5
- 239000007924 injection Substances 0.000 description 5
- 230000007803 itching Effects 0.000 description 5
- 238000005259 measurement Methods 0.000 description 5
- 201000005111 ocular hyperemia Diseases 0.000 description 5
- 239000002997 ophthalmic solution Substances 0.000 description 5
- 239000008213 purified water Substances 0.000 description 5
- 230000004044 response Effects 0.000 description 5
- 150000003839 salts Chemical group 0.000 description 5
- 230000001225 therapeutic effect Effects 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 4
- 239000000064 cholinergic agonist Substances 0.000 description 4
- 238000005094 computer simulation Methods 0.000 description 4
- 210000004087 cornea Anatomy 0.000 description 4
- 238000013461 design Methods 0.000 description 4
- 238000002483 medication Methods 0.000 description 4
- 229940054534 ophthalmic solution Drugs 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 230000002459 sustained effect Effects 0.000 description 4
- YKFROQCFVXOUPW-UHFFFAOYSA-N 4-(methylthio) aniline Chemical compound CSC1=CC=C(N)C=C1 YKFROQCFVXOUPW-UHFFFAOYSA-N 0.000 description 3
- 239000004155 Chlorine dioxide Substances 0.000 description 3
- 108010009685 Cholinergic Receptors Proteins 0.000 description 3
- 206010030348 Open-Angle Glaucoma Diseases 0.000 description 3
- 206010047571 Visual impairment Diseases 0.000 description 3
- 230000002350 accommodative effect Effects 0.000 description 3
- 102000034337 acetylcholine receptors Human genes 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 239000000969 carrier Substances 0.000 description 3
- 235000019398 chlorine dioxide Nutrition 0.000 description 3
- 210000003717 douglas' pouch Anatomy 0.000 description 3
- 230000003547 miosis Effects 0.000 description 3
- 230000004118 muscle contraction Effects 0.000 description 3
- 230000003287 optical effect Effects 0.000 description 3
- 230000036961 partial effect Effects 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- 238000009597 pregnancy test Methods 0.000 description 3
- 208000014733 refractive error Diseases 0.000 description 3
- 230000002207 retinal effect Effects 0.000 description 3
- 230000002123 temporal effect Effects 0.000 description 3
- 241000223783 Glaucoma Species 0.000 description 2
- 206010027646 Miosis Diseases 0.000 description 2
- 230000004308 accommodation Effects 0.000 description 2
- 239000000556 agonist Substances 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 210000001742 aqueous humor Anatomy 0.000 description 2
- 230000036772 blood pressure Effects 0.000 description 2
- OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 description 2
- 230000001713 cholinergic effect Effects 0.000 description 2
- 210000004240 ciliary body Anatomy 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 230000006735 deficit Effects 0.000 description 2
- -1 dihyd rate Sodium chloride Chemical class 0.000 description 2
- 239000003974 emollient agent Substances 0.000 description 2
- 239000003889 eye drop Substances 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 229920003125 hypromellose 2910 Polymers 0.000 description 2
- 229940031672 hypromellose 2910 Drugs 0.000 description 2
- 230000004377 improving vision Effects 0.000 description 2
- GGXICVAJURFBLW-CEYXHVGTSA-N latanoprost Chemical compound CC(C)OC(=O)CCC\C=C/C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1CC[C@@H](O)CCC1=CC=CC=C1 GGXICVAJURFBLW-CEYXHVGTSA-N 0.000 description 2
- 229960001160 latanoprost Drugs 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 230000035479 physiological effects, processes and functions Effects 0.000 description 2
- 229960001963 pilocarpine nitrate Drugs 0.000 description 2
- 238000002203 pretreatment Methods 0.000 description 2
- 201000006366 primary open angle glaucoma Diseases 0.000 description 2
- 238000009097 single-agent therapy Methods 0.000 description 2
- 239000001509 sodium citrate Substances 0.000 description 2
- 208000029257 vision disease Diseases 0.000 description 2
- TWBNMYSKRDRHAT-RCWTXCDDSA-N (S)-timolol hemihydrate Chemical compound O.CC(C)(C)NC[C@H](O)COC1=NSN=C1N1CCOCC1.CC(C)(C)NC[C@H](O)COC1=NSN=C1N1CCOCC1 TWBNMYSKRDRHAT-RCWTXCDDSA-N 0.000 description 1
- QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 241000284156 Clerodendrum quadriloculare Species 0.000 description 1
- 208000028006 Corneal injury Diseases 0.000 description 1
- 206010019196 Head injury Diseases 0.000 description 1
- 208000016297 Holmes-Adie syndrome Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- 208000028389 Nerve injury Diseases 0.000 description 1
- 206010029216 Nervousness Diseases 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- 206010030043 Ocular hypertension Diseases 0.000 description 1
- 206010034972 Photosensitivity reaction Diseases 0.000 description 1
- KCLANYCVBBTKTO-UHFFFAOYSA-N Proparacaine Chemical compound CCCOC1=CC=C(C(=O)OCCN(CC)CC)C=C1N KCLANYCVBBTKTO-UHFFFAOYSA-N 0.000 description 1
- 206010037549 Purpura Diseases 0.000 description 1
- 208000005967 Tonic Pupil Diseases 0.000 description 1
- BGDKAVGWHJFAGW-UHFFFAOYSA-N Tropicamide Chemical compound C=1C=CC=CC=1C(CO)C(=O)N(CC)CC1=CC=NC=C1 BGDKAVGWHJFAGW-UHFFFAOYSA-N 0.000 description 1
- 208000013521 Visual disease Diseases 0.000 description 1
- 238000002679 ablation Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000002730 additional effect Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 239000000048 adrenergic agonist Substances 0.000 description 1
- 229940126157 adrenergic receptor agonist Drugs 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 102000030484 alpha-2 Adrenergic Receptor Human genes 0.000 description 1
- 108020004101 alpha-2 Adrenergic Receptor Proteins 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 229940006133 antiglaucoma drug and miotics carbonic anhydrase inhibitors Drugs 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 239000003489 carbonate dehydratase inhibitor Substances 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- 229960004926 chlorobutanol Drugs 0.000 description 1
- 230000010485 coping Effects 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 230000003500 cycloplegic effect Effects 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 231100000517 death Toxicity 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 150000004683 dihydrates Chemical class 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- NJDNXYGOVLYJHP-UHFFFAOYSA-L disodium;2-(3-oxido-6-oxoxanthen-9-yl)benzoate Chemical compound [Na+].[Na+].[O-]C(=O)C1=CC=CC=C1C1=C2C=CC(=O)C=C2OC2=CC([O-])=CC=C21 NJDNXYGOVLYJHP-UHFFFAOYSA-L 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 238000009509 drug development Methods 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 238000004945 emulsification Methods 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 229940012356 eye drops Drugs 0.000 description 1
- 210000000720 eyelash Anatomy 0.000 description 1
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 1
- 239000003193 general anesthetic agent Substances 0.000 description 1
- 125000001475 halogen functional group Chemical group 0.000 description 1
- 150000003840 hydrochlorides Chemical class 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 description 1
- 229960003943 hypromellose Drugs 0.000 description 1
- 238000005286 illumination Methods 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 230000009191 jumping Effects 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 238000005461 lubrication Methods 0.000 description 1
- 238000007726 management method Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 229940127554 medical product Drugs 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 239000000472 muscarinic agonist Substances 0.000 description 1
- 230000003551 muscarinic effect Effects 0.000 description 1
- 230000008764 nerve damage Effects 0.000 description 1
- 238000011587 new zealand white rabbit Methods 0.000 description 1
- 210000000826 nictitating membrane Anatomy 0.000 description 1
- 230000003764 parasympathetic denervation Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 206010034754 petechiae Diseases 0.000 description 1
- 229960001802 phenylephrine Drugs 0.000 description 1
- SONNWYBIRXJNDC-VIFPVBQESA-N phenylephrine Chemical compound CNC[C@H](O)C1=CC=CC(O)=C1 SONNWYBIRXJNDC-VIFPVBQESA-N 0.000 description 1
- 230000036211 photosensitivity Effects 0.000 description 1
- 229940075005 pilocarpine ophthalmic solution Drugs 0.000 description 1
- 230000036470 plasma concentration Effects 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 229940069328 povidone Drugs 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 229960003981 proparacaine Drugs 0.000 description 1
- 150000003180 prostaglandins Chemical class 0.000 description 1
- 230000004478 pupil constriction Effects 0.000 description 1
- 230000004439 pupillary reactions Effects 0.000 description 1
- 238000011555 rabbit model Methods 0.000 description 1
- 230000004286 retinal pathology Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 238000009781 safety test method Methods 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 208000018316 severe headache Diseases 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- UKLNMMHNWFDKNT-UHFFFAOYSA-M sodium chlorite Chemical compound [Na+].[O-]Cl=O UKLNMMHNWFDKNT-UHFFFAOYSA-M 0.000 description 1
- 229960002218 sodium chlorite Drugs 0.000 description 1
- 210000005070 sphincter Anatomy 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 230000002311 subsequent effect Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- GKCBAIGFKIBETG-UHFFFAOYSA-N tetracaine Chemical compound CCCCNC1=CC=C(C(=O)OCCN(C)C)C=C1 GKCBAIGFKIBETG-UHFFFAOYSA-N 0.000 description 1
- 229960002372 tetracaine Drugs 0.000 description 1
- 229960004605 timolol Drugs 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 231100000041 toxicology testing Toxicity 0.000 description 1
- 210000001585 trabecular meshwork Anatomy 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 229960004791 tropicamide Drugs 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 230000004382 visual function Effects 0.000 description 1
- 230000004393 visual impairment Effects 0.000 description 1
- 238000009736 wetting Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/10—Ophthalmic agents for accommodation disorders, e.g. myopia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/186—Quaternary ammonium compounds, e.g. benzalkonium chloride or cetrimide
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Ophthalmology & Optometry (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Inorganic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862662144P | 2018-04-24 | 2018-04-24 | |
| US62/662,144 | 2018-04-24 | ||
| US201862780117P | 2018-12-14 | 2018-12-14 | |
| US62/780,117 | 2018-12-14 | ||
| US201962790957P | 2019-01-10 | 2019-01-10 | |
| US62/790,957 | 2019-01-10 | ||
| CA3074618A CA3074618C (en) | 2018-04-24 | 2019-04-24 | Presbyopia treatments |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3074618A Division CA3074618C (en) | 2018-04-24 | 2019-04-24 | Presbyopia treatments |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3162141A1 true CA3162141A1 (en) | 2019-10-31 |
Family
ID=66821312
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3162141A Pending CA3162141A1 (en) | 2018-04-24 | 2019-04-24 | Presbyopia treatments |
| CA3074618A Active CA3074618C (en) | 2018-04-24 | 2019-04-24 | Presbyopia treatments |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3074618A Active CA3074618C (en) | 2018-04-24 | 2019-04-24 | Presbyopia treatments |
Country Status (25)
| Country | Link |
|---|---|
| US (4) | US10610518B2 (enExample) |
| EP (2) | EP4066830A1 (enExample) |
| JP (3) | JP6946575B2 (enExample) |
| KR (2) | KR20210005134A (enExample) |
| CN (1) | CN112272558A (enExample) |
| AU (3) | AU2019261598B9 (enExample) |
| BR (1) | BR112020021845A2 (enExample) |
| CA (2) | CA3162141A1 (enExample) |
| CL (1) | CL2020002734A1 (enExample) |
| CO (1) | CO2020014563A2 (enExample) |
| CY (1) | CY1125325T1 (enExample) |
| DK (1) | DK3681500T3 (enExample) |
| ES (1) | ES2920803T5 (enExample) |
| HR (1) | HRP20220762T1 (enExample) |
| HU (1) | HUE058931T2 (enExample) |
| IL (1) | IL278178A (enExample) |
| LT (1) | LT3681500T (enExample) |
| MX (1) | MX2020011301A (enExample) |
| PH (1) | PH12020551766A1 (enExample) |
| PL (1) | PL3681500T3 (enExample) |
| PT (1) | PT3681500T (enExample) |
| RS (1) | RS63360B1 (enExample) |
| SG (1) | SG11202010472XA (enExample) |
| SI (1) | SI3681500T1 (enExample) |
| WO (1) | WO2019209955A2 (enExample) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102654048B1 (ko) | 2017-07-20 | 2024-04-03 | 세인다 파마슈티컬 광저우 코포레이션 | 근시 치료용 조성물 및 방법 |
| US20210251970A1 (en) | 2018-10-10 | 2021-08-19 | Presbyopia Therapies Inc | Compositions and methods for storage stable ophthalmic drugs |
| CN113164451A (zh) | 2018-10-15 | 2021-07-23 | 奥库菲尔制药股份有限公司 | 治疗青光眼的方法和组合物及相关病症 |
| EP3870170A4 (en) | 2018-10-26 | 2022-07-20 | Ocuphire Pharma, Inc. | METHODS AND COMPOSITIONS FOR THE TREATMENT OF PRESBYOPIA, MYDRIASIS AND OTHER EYE DISEASES |
| AU2021338618B2 (en) * | 2020-09-11 | 2024-02-01 | Intratus-Nevada, Inc. | Compositions and methods for treating presbyopia, hyperopia, astigmatism, decreased stereopsis, and decreased contrast sensitivity |
| JP2024505517A (ja) * | 2021-01-28 | 2024-02-06 | グラウコス コーポレイション | 製剤 |
| WO2022232205A1 (en) * | 2021-04-28 | 2022-11-03 | Lenz Therapeutics, Inc. | A method of reducing brow ache |
| CN115368310B (zh) | 2021-05-18 | 2025-06-27 | 奥库菲尔医药公司 | 合成甲磺酸酚妥拉明的方法 |
| EP4433053A4 (en) | 2021-11-17 | 2025-09-17 | Lenz Therapeutics Operations Inc | ACECLIDINE DERIVATIVES, THEIR COMPOSITIONS AND METHODS OF USE |
| CN116350790B (zh) | 2021-12-28 | 2025-02-07 | 沈阳兴齐眼药股份有限公司 | 组合物及其在制备用于治疗老花眼的药物中的用途 |
| US20230270671A1 (en) * | 2022-01-14 | 2023-08-31 | Somerset Therapeutics, Llc | Pharmaceutically stable pilocarpine formulations with substantially reduced buffer content and related methods |
| US11969410B2 (en) | 2022-02-09 | 2024-04-30 | Somerset Therapeutics, Llc | Low pH pilocarpine and brimonidine compound formulations and related methods |
| CN119584954A (zh) | 2022-04-21 | 2025-03-07 | 格劳科斯公司 | 眼用局部乳膏组合物 |
| CN119546278A (zh) | 2022-05-18 | 2025-02-28 | 格劳科斯公司 | 两性离子在眼用局部乳膏组合物和制剂中的新应用 |
| CN117243888A (zh) * | 2023-09-22 | 2023-12-19 | 南京海纳制药有限公司 | 一种含有盐酸毛果芸香碱滴眼水性药物组合物及其制备方法 |
| US12414942B1 (en) | 2024-03-15 | 2025-09-16 | Lenz Therapeutics Operations, Inc. | Compositions, methods, and systems for treating presbyopia |
Family Cites Families (74)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4474751A (en) | 1983-05-16 | 1984-10-02 | Merck & Co., Inc. | Ophthalmic drug delivery system utilizing thermosetting gels |
| US4851521A (en) | 1985-07-08 | 1989-07-25 | Fidia, S.P.A. | Esters of hyaluronic acid |
| CA2003198C (en) | 1988-11-29 | 1995-03-21 | Anthony J. Dziabo, Jr. | Aqueous ophthalmic solutions and method for preserving same |
| US5122522A (en) | 1989-06-21 | 1992-06-16 | The Trustees Of The University Of Pennsylvania | Treatment and control of ocular development |
| US5055467A (en) | 1989-11-13 | 1991-10-08 | Allergan, Inc. | Pharmaceutical epinephrine-pilocarpine compounds |
| US5496471A (en) | 1990-01-08 | 1996-03-05 | Ciba-Geigy Corporation | Apparatus for removing components from solutions |
| US5776916A (en) | 1990-07-10 | 1998-07-07 | Gramer; Eugen | Medicament for reducing the intraocular pressure |
| JP2536806B2 (ja) | 1991-03-27 | 1996-09-25 | アルコン ラボラトリーズ インコーポレイテッド | ゲル化多糖類と微粉砕された薬剤担体とを組み合わせた局部眼科用組成物 |
| US5459133A (en) | 1992-06-05 | 1995-10-17 | Telor Ophthalmic Pharmaceuticals, Inc. | Methods and products for treating presbyopia |
| WO1994001096A1 (en) | 1992-07-02 | 1994-01-20 | Telor Ophthalmic Pharmaceuticals, Inc. | Methods and products for treating presbyopia |
| SE512871C2 (sv) | 1992-08-20 | 2000-05-29 | Santen Oy | Oftalmologisk beredning innehållande pilokarpin och ytterligare medel för behandling av okular hypertension |
| AU5599594A (en) * | 1992-11-16 | 1994-06-08 | Ciba-Geigy Ag | Polyvinyl alcohol/borate ophthalmic drug delivery system |
| US5422116A (en) | 1994-02-18 | 1995-06-06 | Ciba-Geigy Corporation | Liquid ophthalmic sustained release delivery system |
| SE9401109D0 (sv) | 1994-03-31 | 1994-03-31 | Leiras Oy | Opthalmic composition II |
| US5574518A (en) | 1995-01-10 | 1996-11-12 | Les Laboratoires Opti-Centre Inc. | System incorporation two different sphero-non-spherical contact lenses for correcting presbytia |
| US5612027A (en) | 1995-04-18 | 1997-03-18 | Galin; Miles A. | Controlled release of miotic and mydriatic drugs in the anterior chamber |
| US6291466B1 (en) * | 1998-07-30 | 2001-09-18 | Allergan Sales, Inc. | Cholinergic agents in the treatment of presbyopia |
| US6164282A (en) | 1999-01-27 | 2000-12-26 | Allergan Sales, Inc. | Methods for restoring and/or enhancing accommodation in pseudo phakia |
| CH693625A5 (it) | 1999-02-18 | 2003-11-28 | Inpharma Sa | Composizioni farmaceutiche contenenti composti ad attività promotrice di assorbimento di principi attivi. |
| IT1306135B1 (it) * | 1999-04-26 | 2001-05-30 | Farmigea Spa | Composizioni oftalmiche per il trattamento delle turbe visivecaratterizzate da ridotta sensibilita' al contrasto. |
| US6420407B1 (en) | 1999-09-16 | 2002-07-16 | Gerald Horn | Ophthalmic formulation which modulates dilation |
| EP1214065A4 (en) | 1999-09-16 | 2009-01-07 | Ocularis Pharma Inc | METHOD USING THE ALPHA AGONIST TO OPTIMIZE THE SIZE OF THE PUPIL |
| TWI227143B (en) | 1999-12-15 | 2005-02-01 | Guo-Jiun Sung | In situ gel formation for ophthalmic delivery by combining Pluronic/Carbopol medic composition and its preparing method |
| US6218428B1 (en) | 2000-04-28 | 2001-04-17 | Emil Chynn | Ophthalmic composition |
| PE20020146A1 (es) | 2000-07-13 | 2002-03-31 | Upjohn Co | Formulacion oftalmica que comprende un inhibidor de ciclooxigenasa-2 (cox-2) |
| AU2001291159A1 (en) | 2000-09-20 | 2002-04-02 | Shahinian Jr., Lee | Self-preserved nasal, inhalable, and topical ophthalmic preparations and medications |
| US6273092B1 (en) | 2000-09-22 | 2001-08-14 | Gerard M. Nolan | Methods for treating various eye disorders |
| ITMI20010708A1 (it) | 2001-04-03 | 2002-10-03 | Alessandro Randazzo | Trattamento farmacologico degli aloni notturni e delle immagini fantasma con parasimpaticomimetici diluiti aceclidina/pilocarpina dopo inter |
| US20030139737A1 (en) | 2002-01-24 | 2003-07-24 | J.T. Lin | Method and apparatus for treatment of presbyopia by lens relaxation and anterior shift |
| ES2397574T3 (es) | 2002-07-30 | 2013-03-08 | Omeros Corporation | Procedimiento y soluciones de irrigación oftalmológica |
| US20050261641A1 (en) | 2002-09-26 | 2005-11-24 | Warchol Mark P | Method for ophthalmic administration of medicament |
| US20070211212A1 (en) | 2002-09-26 | 2007-09-13 | Percy Bennwik | Eye state sensor |
| US20040078009A1 (en) | 2002-10-17 | 2004-04-22 | Lin J. T. | Method and apparatus for the treatment of presbyopia and other eye disorders combining pharmocological and surgical means |
| US20050205101A1 (en) * | 2002-10-17 | 2005-09-22 | Lin J T | Combined pharmocological and surgical method and system for the treatment of eye disorders |
| US20060177430A1 (en) | 2002-12-20 | 2006-08-10 | Chakshu Research Inc | Treatment of ocular disorders with ophthalmic formulations containing methylsulfonylmethane as a transport enhancer |
| NZ540885A (en) | 2002-12-20 | 2009-02-28 | Chakshu Res Inc | Ophthalmic formulation for the prevention and treatment of ocular conditions |
| CA2517145C (en) | 2003-03-05 | 2017-08-01 | Halozyme, Inc. | Soluble hyaluronidase glycoprotein (shasegp), process for preparing the same, uses and pharmaceutical compositions comprising thereof |
| US20050119262A1 (en) | 2003-08-21 | 2005-06-02 | Pharmacia Corporation | Method for preventing or treating an optic neuropathy with a cox-2 inhibitor and an intraocular pressure reducing agent |
| JP4308255B2 (ja) | 2004-05-21 | 2009-08-05 | 千寿製薬株式会社 | ムスカリン受容体作動薬を含有する眼科用経皮吸収型製剤 |
| US20050279369A1 (en) | 2004-06-21 | 2005-12-22 | Lin J T | Method and apparatus for the treatment of presbyopia and glaucoma by ciliary body ablation |
| JP2008517671A (ja) | 2004-10-22 | 2008-05-29 | アキュフォーカス・インコーポレーテッド | 光学装置を目の軸に位置合わせするためのシステム及び方法 |
| BRPI0615432A2 (pt) | 2005-09-02 | 2011-05-17 | Theravida Inc | composição farmacêutica, e, uso de compostos |
| US8158152B2 (en) | 2005-11-18 | 2012-04-17 | Scidose Llc | Lyophilization process and products obtained thereby |
| CA2658394C (en) | 2006-07-12 | 2016-08-16 | University Of Tennessee Research Foundation | Substituted acylanilides and methods of use thereof |
| EP1938839B1 (en) | 2006-12-18 | 2009-08-19 | Jorge Luis Benozzi | Ophthalmic compositions of parasympathetic stimulants and anti-inflammatories for use in the treatment of presbyopia |
| BRPI0819081A8 (pt) | 2007-10-08 | 2016-08-30 | Fovea Pharmaceuticals Sa | Formulação oftálmica aquosa, processo para preparar a mesma, e, método para inibir, tratar ou prevenir doenças oculares e doença ou condição relacionada, em um paciente em necessidade de tal tratamento |
| GB0724558D0 (en) | 2007-12-15 | 2008-01-30 | Sharma Anant | Optical correction |
| AU2015202175A1 (en) | 2007-12-15 | 2015-05-14 | Anant Sharma | Optical correction |
| WO2010125416A1 (en) | 2009-04-27 | 2010-11-04 | Raouf Rekik | Drug delivery to the anterior and posterior segments of the eye |
| WO2010135731A1 (en) | 2009-05-22 | 2010-11-25 | Kaufman Herbert E | Preparations and methods for ameliorating or reducing presbyopia |
| US8299079B2 (en) | 2009-05-22 | 2012-10-30 | Kaufman Herbert E | Preparations and methods for ameliorating or reducing presbyopia |
| TW201109325A (en) | 2009-07-30 | 2011-03-16 | Wakamoto Pharma Co Ltd | Aqueous composition for eye drops |
| AR081049A1 (es) | 2010-08-17 | 2012-06-06 | Gonzalez Santos Alejandro Raul | Medicamento oftalmico para el tratamiento de la hipermetropia |
| US9119772B2 (en) * | 2011-01-26 | 2015-09-01 | Allergan, Inc. | Androgen composition for treating an opthalmic condition |
| BR112014006607A2 (pt) | 2011-09-20 | 2017-04-25 | Allergan Inc | composições e métodos para tratamento de presbiopia, hiperopia leve e astigmatismo irregular |
| KR20140103099A (ko) | 2011-10-12 | 2014-08-25 | 아센디스 파마 옵탈몰로지 디비젼 에이/에스 | 안구 병태의 예방 및 치료 |
| RU2014129268A (ru) | 2011-12-16 | 2016-02-10 | Аллерган, Инк. | Офтальмологические составы, которые содержат привитые сополимеры поливинилкапролактам-поливинилацетат-полиэтиленгликоля |
| EP2630952A1 (en) | 2012-02-23 | 2013-08-28 | Novagali Pharma S.A. | Self-preserved oil dispersions comprising boric acid |
| US10507245B2 (en) | 2012-07-19 | 2019-12-17 | Luis Felipe Vejarano Restrepo | Ophthalmic formulation and method for ameliorating presbyopia |
| EP2950800B1 (en) | 2013-02-01 | 2020-09-09 | Ocuphire Pharma, Inc. | Methods and compositions for daily ophthalmic administration of phentolamine to improve visual performance |
| CA2899339C (en) | 2013-02-01 | 2021-07-06 | Ocularis Pharma, Llc | Aqueous ophthalmic solutions of phentolamine and medical uses thereof |
| US9314427B2 (en) | 2013-08-28 | 2016-04-19 | Presbyopia Therapies Llc | Compositions and methods for the improvement of distance vision and the treatment of refractive errors of the eye |
| US9968594B2 (en) | 2013-08-28 | 2018-05-15 | Presbyopia Therapies Llc | Compositions and methods for the treatment of presbyopia |
| US9089562B2 (en) | 2013-08-28 | 2015-07-28 | Presbyopia Therapies Llc | Compositions and methods for the treatment of presbyopia |
| US8859623B1 (en) | 2013-11-14 | 2014-10-14 | Paragon BioTeck, Inc. | Methods and compositions of stable phenylephrine formulations |
| ES2538551B1 (es) | 2013-12-20 | 2016-01-13 | Eurocanarias Oftalmológica, Sl | Composición Oftálmica para la corrección de la presbicia |
| ES2834334T3 (es) | 2014-01-10 | 2021-06-17 | Santen Pharmaceutical Co Ltd | Preparación farmacéutica que incluye compuesto de ácido piridilaminoacético |
| CN106456584A (zh) | 2014-02-11 | 2017-02-22 | 阿拉西斯医药公司 | 用于矫正老视的药理学眼科用组合物和其施用 |
| US11052094B2 (en) | 2015-05-29 | 2021-07-06 | Sydnexis, Inc. | D2O stabilized pharmaceutical formulations |
| US20190000808A1 (en) | 2015-07-13 | 2019-01-03 | Allergan, Inc. | Composition and methods for the treatment of blephopharoptosis |
| CH711969A2 (it) | 2015-12-29 | 2017-06-30 | Pinelli Roberto | Composizione per il trattamento della presbiopia. |
| US10231968B2 (en) | 2016-08-01 | 2019-03-19 | David R. Hardten | Medicinal solution to be continuously or pulse-delivered to the eye for treating ophthalmological conditions/maladies |
| CN116726006A (zh) | 2016-08-19 | 2023-09-12 | 阿拉西斯医药公司 | 眼科药物组合物及其相关用途 |
| EP4241759A1 (en) | 2016-10-12 | 2023-09-13 | PS Therapy, Inc. | Artificial tear, contact lens and drug vehicle compositions and methods of use thereof |
-
2019
- 2019-04-24 KR KR1020207033656A patent/KR20210005134A/ko not_active Ceased
- 2019-04-24 HR HRP20220762TT patent/HRP20220762T1/hr unknown
- 2019-04-24 RS RS20220575A patent/RS63360B1/sr unknown
- 2019-04-24 SG SG11202010472XA patent/SG11202010472XA/en unknown
- 2019-04-24 ES ES19729883T patent/ES2920803T5/es active Active
- 2019-04-24 CA CA3162141A patent/CA3162141A1/en active Pending
- 2019-04-24 CN CN201980037652.3A patent/CN112272558A/zh active Pending
- 2019-04-24 MX MX2020011301A patent/MX2020011301A/es unknown
- 2019-04-24 PL PL19729883.9T patent/PL3681500T3/pl unknown
- 2019-04-24 AU AU2019261598A patent/AU2019261598B9/en not_active Ceased
- 2019-04-24 LT LTEPPCT/US2019/028917T patent/LT3681500T/lt unknown
- 2019-04-24 WO PCT/US2019/028917 patent/WO2019209955A2/en not_active Ceased
- 2019-04-24 EP EP22160205.5A patent/EP4066830A1/en active Pending
- 2019-04-24 SI SI201930260T patent/SI3681500T1/sl unknown
- 2019-04-24 JP JP2020559558A patent/JP6946575B2/ja active Active
- 2019-04-24 CA CA3074618A patent/CA3074618C/en active Active
- 2019-04-24 KR KR1020237017632A patent/KR20230079489A/ko active Pending
- 2019-04-24 PT PT197298839T patent/PT3681500T/pt unknown
- 2019-04-24 US US16/393,175 patent/US10610518B2/en active Active
- 2019-04-24 HU HUE19729883A patent/HUE058931T2/hu unknown
- 2019-04-24 DK DK19729883.9T patent/DK3681500T3/da active
- 2019-04-24 BR BR112020021845-6A patent/BR112020021845A2/pt not_active IP Right Cessation
- 2019-04-24 EP EP19729883.9A patent/EP3681500B2/en active Active
-
2020
- 2020-02-14 US US16/791,039 patent/US11285134B2/en active Active
- 2020-05-21 AU AU2020203311A patent/AU2020203311A1/en not_active Abandoned
- 2020-10-20 IL IL278178A patent/IL278178A/en unknown
- 2020-10-22 CL CL2020002734A patent/CL2020002734A1/es unknown
- 2020-10-23 PH PH12020551766A patent/PH12020551766A1/en unknown
- 2020-11-24 CO CONC2020/0014563A patent/CO2020014563A2/es unknown
-
2021
- 2021-09-15 JP JP2021150116A patent/JP7470667B2/ja active Active
-
2022
- 2022-01-12 US US17/647,813 patent/US20220241245A1/en not_active Abandoned
- 2022-02-18 AU AU2022201106A patent/AU2022201106A1/en not_active Abandoned
- 2022-06-22 CY CY20221100430T patent/CY1125325T1/el unknown
-
2024
- 2024-03-29 US US18/621,624 patent/US20240382462A1/en not_active Abandoned
- 2024-04-08 JP JP2024062082A patent/JP2024096131A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20240382462A1 (en) | Presbyopia treatments | |
| JP7297308B2 (ja) | 眼科用医薬組成物及びそれに関する使用 | |
| JP2022505950A (ja) | 老眼、散瞳、および他の眼障害の治療のための方法および組成物 | |
| BRPI0821683B1 (pt) | uso de um agonista parassimpático e de um antagonista simpático ou um agonista simpático para tratar presbiopia, miopia, hipermetropia, emetropia e/ou astigmatismo, e/ou para melhorar a visão noturna ou de baixa luz | |
| JP2022508715A (ja) | 緑内障および関連状態の処置のための方法および組成物 | |
| Kaback et al. | Intraocular pressure-lowering efficacy of brinzolamide 1%/timolol 0.5% fixed combination compared with brinzolamide 1% and timolol 0.5% | |
| US20040013729A1 (en) | Single-drop multiple-agent composition for topical delivery to the eye | |
| Diestelhorst et al. | The additive intraocular pressure-lowering effect of latanoprost 0.005% daily once and pilocarpine 2% tid in patients with open-angle glaucoma or ocular hypertension: a 6-month, randomized, multicenter study | |
| HK40081663A (en) | Use of pilocarpine hydrochloride for the treatment of ocular conditions | |
| HK40034331A (en) | Use of pilocarpine hydrochloride for the treatment of presbyopia | |
| HK40034331B (en) | Use of pilocarpine hydrochloride for the treatment of presbyopia | |
| Kim et al. | Effects of brimonidine timolol fixed combination therapy on anterior ocular segment configuration | |
| US20250288567A1 (en) | Pharmaceutical composition for treating presbyopia | |
| Galeana | Pharmacologic compound to mitigate presbyopia symptoms | |
| Chmielarz-Czarnocińska et al. | Ophthalmic applications of cyclopentolate | |
| Galeana | Prospective Interventional Non-Comparative Non-Randomized Clinical Study of A Topical Synergic Compound to Mitigate Presbyopia Effects | |
| EA047817B1 (ru) | Композиции и способы лечения пресбиопии, дальнозоркости, астигматизма, сниженного стереопсиса и сниженной контрастной чувствительности |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20220609 |
|
| EEER | Examination request |
Effective date: 20220609 |
|
| EEER | Examination request |
Effective date: 20220609 |
|
| EEER | Examination request |
Effective date: 20220609 |
|
| EEER | Examination request |
Effective date: 20220609 |
|
| EEER | Examination request |
Effective date: 20220609 |